Connexios: Harnessing the Indian cost advantage in network biology
This article was originally published in Scrip
Imagine if a start-up company could afford to hire enough high-calibre scientists to spend years creating a detailed map of a broad and complex pathology like metabolic disease, incorporating large amounts of cellular and molecular biological data, into which it could plug further swathes of clinical information. Imagine if it was then able to evaluate existing drug R&D against this map, and identify promising areas for potential future drug discovery and development, which it would then proceed to carry out itself. All with the financial backing of an enthusiastic private investor. It seems unlikely, but this is precisely what Connexios Life Sciences has done. Scrip's companies editor Eleanor Malone met CEO Dr Suri Venkatachalam to find out more.
You may also be interested in...
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.
Sanofi pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.